PMID- 31102271
OWN - NLM
STAT- MEDLINE
DCOM- 20200622
LR  - 20200622
IS  - 1097-4652 (Electronic)
IS  - 0021-9541 (Linking)
VI  - 234
IP  - 12
DP  - 2019 Dec
TI  - Histone deacetylase inhibitor, AR-42, exerts antitumor effects by inducing 
      apoptosis and cell cycle arrest in Y79 cells.
PG  - 22411-22423
LID - 10.1002/jcp.28806 [doi]
AB  - Retinoblastoma (RB) is the most common type of intraocular malignant tumor that 
      occurs in childhood. AR-42, a member of a newly discovered class of 
      phenylbutyrate-derived histone deacetylase inhibitors, exerts antitumor effects 
      on many cancers. In the present study, we initially evaluated the effect of AR-42 
      towards RB cells and explored the underlying mechanism in this disease. Our 
      results found that AR-42 showed powerful antitumor effects at low micromolar 
      concentrations by inhibiting cell viability, blocking cell cycle, stimulating 
      apoptosis in vitro, and suppressing RB growth in a mouse subcutaneous tumor 
      xenograft model. Furthermore, the AKT/nuclear factor-kappa B signaling pathway 
      was disrupted in Y79 cells treated with AR-42. In conclusion, we propose that 
      AR-42 might be a promising drug treatment for RB.
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - Duan, Sujuan
AU  - Duan S
AD  - Department of Ophthalmology, The Third Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi, People's Republic of China.
AD  - Jiangxi Key Laboratory of Cancer Metastasis and Precision Treatment, The Third 
      Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic 
      of China.
FAU - Gong, Xiaona
AU  - Gong X
AD  - Department of Ophthalmology, Xiangyang First People's Hospital, Xiangyang, China.
FAU - Liu, Xing
AU  - Liu X
AD  - Medical Department of Graduate School, Nanchang University, Nanchang, Jiangxi, 
      People's Republic of China.
FAU - Cui, Wenwen
AU  - Cui W
AD  - Medical Department of Graduate School, Nanchang University, Nanchang, Jiangxi, 
      People's Republic of China.
FAU - Chen, Kaddie
AU  - Chen K
AD  - Jiangxi Key Laboratory of Cancer Metastasis and Precision Treatment, The Third 
      Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic 
      of China.
FAU - Mao, Longbing
AU  - Mao L
AD  - Medical Department of Graduate School, Nanchang University, Nanchang, Jiangxi, 
      People's Republic of China.
FAU - Jun, Sun
AU  - Jun S
AD  - First Clinical Department, Medical School of Nanchang University, Nanchang, 
      Jiangxi, People's Republic of China.
FAU - Zhou, Ruihao
AU  - Zhou R
AD  - Medical Department of Graduate School, Nanchang University, Nanchang, Jiangxi, 
      People's Republic of China.
FAU - Sang, Yi
AU  - Sang Y
AD  - Jiangxi Key Laboratory of Cancer Metastasis and Precision Treatment, The Third 
      Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic 
      of China.
FAU - Huang, Guofu
AU  - Huang G
AUID- ORCID: 0000-0002-4804-8631
AD  - Department of Ophthalmology, The Third Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi, People's Republic of China.
AD  - Jiangxi Key Laboratory of Cancer Metastasis and Precision Treatment, The Third 
      Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic 
      of China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190517
PL  - United States
TA  - J Cell Physiol
JT  - Journal of cellular physiology
JID - 0050222
RN  - 0 (OSU-HDAC42 compound)
RN  - 0 (Phenylbutyrates)
SB  - IM
MH  - Animals
MH  - Apoptosis/*drug effects
MH  - Cell Cycle Checkpoints/*drug effects
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Mice
MH  - Mice, Nude
MH  - Neoplasms, Experimental/drug therapy
MH  - Phenylbutyrates/*pharmacology
MH  - Retinoblastoma/*drug therapy
OTO - NOTNLM
OT  - AKT/NF-kappaB
OT  - AR-42
OT  - Y79
OT  - retinoblastoma
EDAT- 2019/05/19 06:00
MHDA- 2020/06/23 06:00
CRDT- 2019/05/19 06:00
PHST- 2019/01/14 00:00 [received]
PHST- 2019/04/24 00:00 [accepted]
PHST- 2019/05/19 06:00 [pubmed]
PHST- 2020/06/23 06:00 [medline]
PHST- 2019/05/19 06:00 [entrez]
AID - 10.1002/jcp.28806 [doi]
PST - ppublish
SO  - J Cell Physiol. 2019 Dec;234(12):22411-22423. doi: 10.1002/jcp.28806. Epub 2019 
      May 17.